Exagen’s Strategic Growth and Innovation Drive Buy Rating Amid Market Expansion
I'm PortAI, I can summarize articles.
Exagen received a Buy rating from Kyle Mikson CFA at Canaccord Genuity, with a $15.00 price target, due to its strategic growth and innovation. The company showed strong Q3 2025 performance, expanding in existing accounts and acquiring new customers. Exagen operates in a promising market for autoimmune evaluations and is enhancing services and product innovation. BTIG also reiterated a Buy rating with the same price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments